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Original Article
Hydroxyapatite (HA) is a porous non-toxic calcium-phos-
phate salt complex with high biocompatibility that is both 
strong and lightweight. Following the introduction of HA 
by Perry in 1985 [1,2], it has become widely used following 
enucleation or evisceration because of its excellent cosmet-
ic and functional properties [1,2]. Indeed, the porous struc-
ture of HA allows for fibrovascular tissue ingrowth, which 
reduces migration and extrusion. However, one of the dis-
advantages of HA is that the extraocular muscles may be-
come directly attached to the surface. Due to the rough 
surface properties of HA, these attachments may in turn 
lead to HA exposure [3].
Various wrapping materials have been studied as a way 
to allow extraocular muscles to attach to HA implants in 
order to prevent complications such as exposure. Examples 
of wrapping materials include banked sclera, autogenous 
fascia lata, cadaver dura mater, and synthetic materials [4-
6]. These materials act as a barrier that protect the anterior 
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Purpose: To describe cases of exposed hydroxyapatite (HA) implants wrapped with the synthetic dura substi-
tute Neuro-Patch treated via simple Neuro-Patch removal.
Methods: The medical records of seven patients who experienced exposure of their HA implant were reviewed. 
All patients had been enucleated and implanted with HA wrapped with Neuro-Patch. For treatment, Neu-
ro-Patch was removed to the greatest extent possible. After applying local anesthesia with lidocaine, blunt 
dissection was performed to separate the conjunctiva and Neuro-Patch via the site of exposure. Pressure was 
applied to the remaining Neuro-Patch with forceps and removed with scissors.
Results: Neuro-Patch was visible at the area of exposure in all patients. No surgery beyond initial Neuro-Patch 
removal was necessary in six of the seven patients. In five cases, the exposed area began to heal rapidly af-
ter Neuro-patch removal without primary closure of the defect. In one case, the Neuro-Patch material and all 
necrotic tissue was removed aggressively due to inflammation around the orbital implant. Lastly, an infection 
was noted in one case, prompting complete removal of the Neuro-Patch–wrapped HA implant.
Conclusions: Wrapping material may hinder implant vascularization. Exposure of HA in wrapped implants can 
be successfully treated by a simple removal procedure if detected and managed early.
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part of the orbital soft tissues against the rough surface of 
HA. Banked sclera and cadaver dura mater carry the risk 
of disease transmission if donor tissues are not properly 
screened and processed, including human immunodefi-
ciency virus, Creutzfeldt-Jakob disease, and hepatitis [7,8]. 
On the other hand, autogenous fascia lata has no associated 
risk of infectious disease transmission, but functional and 
cosmetic problems can occur at the donor site.
The synthetic dura substitute Neuro-Patch (Aesculap 
AG, Tuttlingen, Germany) is a non-absorbable, micropo-
rous, non-woven material consisting of cleaned aliphatic 
polyester urethane. Neuro-Patch is commonly used in neu-
rosurgery for cases involving dural defects or cerebrospi-
nal f luid decompression. Neuro-Patch is also used as a 
wrapping material for orbital implants because it is rela-
tively inexpensive, easy to obtain, and allows for fibrovas-
cular tissue ingrowth [9]. In the present study, we describe 
seven cases of exposure of HA implants wrapped with 
Neuro-Patch that were successfully treated by simple Neu-
ro-Patch removal or total implant removal. In cases involv-
ing simple Neuro-Patch removal, exposed HA sponta-
neously healed without the need for primary closure of the 
conjunctiva.
Materials and Methods
This retrospective case review-based study was approved 
by the institutional review board of Severance Hospi tal, 
Yonsei University College of Medicine, Seoul, Korea (4-
2018-0696). This study conformed to the Declaration of 
Helsinki and written informed consent was obtained. The 
medical records of patients who visited our clinic for HA 
exposure between February 2016 and January 2018 were 
reviewed. We identified all patients who had been enucle-
ated, given an HA implant wrapped with Neuro-Patch, and 
presented to our outpatient clinic with an exposed implant. 
Neuro-Patch was initially removed to the greatest extent 
possible through the exposed area. A lidocaine epinephrine 
solution (Xylocaine 2%, AstraZeneca, London, United 
Kingdom) was injected at the conjunctiva and deep tissues 
around the exposed area. After blunt dissection to separate 
the conjunctiva and Neuro-Patch via the site of exposure, 
Neuro-Patch was pulled with forceps and removed with 
scissors. If the implant was severely infected, the implant 
was removed together with Neuro-Patch. Ofloxacin oint-
ment was applied at the site of exposure, which was then 
patched. Patients were prohibited from wearing ocular 
prostheses, and instead used a plastic conformer for 1 to 2 
months until the exposed implant was covered with a con-
junctival layer. If the exposure was located at the medial or 
lateral canthal aspect of the implant, the corner of the con-
former was shaved by an ocularist using a hand drill to 
achieve a round shape.
Results
Seven patients with exposure of an implant that had 
been previously wrapped with Neuro-Patch were retro-
spectively collated, and the data derived from these pa-
tients are presented in Table 1. The age of patients ranged 
Table 1. Clinical data derived from seven patients with Neuro-Patch–wrapped hydroxyapatite implants
Case
no.
Age
(yr)/sex Diagnosis
Implant 
diameter
(mm)
Exposure
time after 
implantation (yr)
Exposure size*
(mm) Treatment
Post-treatment 
follow-up period 
(mon)
1 46/M CM 20 4 4 × 2 NR 22
2 11/F CM 18 4 9 × 9 NR 20
3 53/F CM 18 7 4 × 4 NR 29
4 44/F Anophthalmos 18 7 7 × 6 NR 22
5 80/F CM 21 5 12 × 9 NR 16
6 49/M TP 20 15 5 × 5 NC 25
7 62/F TP 16 15 10 × 10 I R 10
CM = choroidal melanoma; NR = Neuro-Patch removal only; TP = traumatic phthisis; NC = Neuro-Patch removal and primary closure; 
IR = orbital implant removal.
*Horizontal × vertical.
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from 11 to 80 years, two were male, and five were female. 
Four patients had undergone enucleation surgery due to 
choroidal melanoma, two experienced eye trauma prior to 
enucleation, and one patient had undergone secondary HA 
implantation due to anophthalmos. The duration of the in-
terval between orbital implantation and exposure ranged 
from 4 to 15 years.
In all patients, Neuro-Patch was visible at the site of ex-
posure. In six of the seven patients (cases 1 to 6) no addi-
tional surgery was necessary other than Neuro-Patch re-
moval. In cases 1 to 5, Neuro-Patch was putatively 
removed via the exposed area and the exposed HA began 
to heal rapidly without any primary closure of the defect. 
Conjunctival epithelium began to grow and migrate over 
the exposed HA as early as 1 week after surgery, and the 
exposure had disappeared completely by the last follow-up 
(Fig. 1A-1E).
In case 4, although the overlying conjunctival tissues 
were relatively thinner than surrounding tissues, full 
growth of the fibrovascular tissue over the area of HA ex-
posure was evident (Fig. 1D). The patient in case 6 visited 
the clinic complaining of copious discharge from the sock-
et, orbital pain, and recurrent incidence of granulation tis-
sues (Fig. 1F). The Neuro-Patch was removed—at first 
partially—via the exposed area at an outpatient clinic in 
the same manner as in cases 1 to 5; however, there was in-
complete resolution of symptoms. Subsequent computed 
tomography revealed a severe inf lammatory reaction 
around the entire HA implant (Fig. 2A), although bacterial 
cultures were negative. Under general anesthesia, all of the 
Neuro-Patch as well as necrotic tissues around the orbital 
implant were aggressively removed, resulting in complete 
resolution of exposure and inflammation (Fig. 2B). Remov-
al of the implant was not deemed necessary at any point 
throughout the follow-up period.
The Neuro-Patch material was not strongly attached to 
the HA implant surface in cases 1 to 6, and instead was 
easily dethatched. Symptoms of discharge and foreign 
body sensation rapidly disappeared after the procedure. 
The follow-up periods in cases 1 to 6 ranged from 16 to 29 
months, with a median of 22 months. As of the last fol-
low-up, there had been no re-exposure of the implant in 
cases 1 to 6. 
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Fig. 1. Anophthalmic sockets in cases 1 to 6. (A) Case 1, (B) case 2, (C) case 3, (D) case 4, (E) case 5, and (F) case 6. The upper images 
in panels show areas of exposed Neuro-Patch of various sizes and lower images show well healed areas of former exposure after Neu-
ro-Patch removal. The formerly exposed areas remained well healed at the last follow-up examination in all six cases. Written informed 
consent from the patient was obtained.
Fig. 2. Case 6. (A) Preoperative computed tomography showing 
inflammation around the orbital implant (arrow). (B) Postopera-
tive computed tomography showing remarkable improvement of 
the inflammation around the orbital implant. Written informed 
consent from the patient was obtained.
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B
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In case 7, an infection of the HA by pseudomonas was 
identified on bacterial culture (Fig. 3A-3C). A combined 
procedure was subsequently performed in which the Neu-
ro-Patch-wrapped HA implant was completely removed 
followed by dermal fat grafting under general anesthesia. 
Postoperatively, none of the previously reported symptoms 
including pain, discharge, and granulation tissue occurred 
during the follow-up period.
Discussion
HA is widely used as an orbital implant following enu-
cleation, usually along with a wrapping material. Hu-
man-derived wrapping materials such as banked sclera 
and cadaver dura mater have associated risks of transmis-
sion of infection from donor tissue [10,11]. Thus, several 
studies have been performed to identify an ideal wrapping 
material to replace human-derived material for HA im-
plants. Such materials must be biocompatible, inexpensive, 
sterile, resistant to infection, and easy to produce. Exam-
ples of synthetic materials that have been investigated in-
clude polyglycolic acid mesh and polyglactin mesh [12-14].
Neuro-Patch is one of the synthetic wrapping materials 
originally manufactured as a dura substitute [15]. Accord-
ing to its product description, the microporous structure of 
Neuro-Patch allows for immediate inward migration of fi-
broblasts and anchoring of the graft in tissue by collagen 
without an accompanying inflammatory reaction. Howev-
er, there have been several documented neurosurgery cases 
where associated complications such as necrosis, tissue in-
fection, and inflammation occurred after predominant use 
of Neuro-Patch [16,17].
Heimann et al. [18] observed marked inflammatory reac-
tions involving infiltration by giant foreign body cells, mac-
rophages, plasma cells, and neutrophilic/eosinophilic gran-
ulocytes in the micropores of Neuro-Patch inserted in the 
orbit, but only a very small number of fibroblasts. They also 
noted weak and thin adhesions between wrapping material 
and orbital connective tissue. In these cases, it may be that 
the Neuro-Patch blocked passage of fibroblasts into HA, re-
sulting in reduced vascularization of the HA micropores 
and adhesion to both Tenon’s capsule and conjunctiva. Sim-
ilarly, we noted that the Neuro-Patch was not closely ad-
hered to the HA implant in our patients, but rather was al-
most entirely separated from the HA surface. In all cases, 
the Neuro-Patch wrapping material had blocked microvas-
culature and fibrous tissue growth into the HA implant.
Exposure of an HA implant is a dangerous complication, 
and various methods have been applied to solve the prob-
lem. Dermis fat grafting or oral mucosa grafting with HA 
drilling are the current standard treatments for HA expo-
sure [19]. However, in the cases described in this study, 
complete healing of the area of exposure was achieved af-
ter simple Neuro-Patch removal. Specifically, we found 
that Neuro-Patch was easily detached and removed via the 
exposed area, and within a few days of partial removal of 
Neuro-Patch fragments without any primary closure, nat-
ural healing of the dehiscence was achieved. In most of the 
small sized exposure cases, surgery was performed in the 
outpatient clinic rather than the operating room, and no 
additional procedures or surgery were required.
Based on our findings, we recommend early intervention 
by way of simple removal of Neuro-Patch as soon as a 
small exposure is discovered. This simple approach is cost 
effective and may facilitate rapid recovery from symp-
toms. However, in cases involving severe inf lammation, 
aggressive removal of Neuro-Patch is required. In the case 
in our study where this was required, removal of Neu-
ro-Patch without implant removal was sufficient.
In conclusion, we retrospectively collated and reviewed 
several cases of HA exposure associated with Neuro-Patch 
wrapping. Surprisingly, we found that the Neuro-Patch 
wrapping had blocked fibrovascular tissue growth into HA 
implants, rather than protecting HA surfaces from anterior 
soft tissues. Our results suggest that this wrapping materi-
al may also hinder implant vascularization. Small areas of 
exposure of Neuro-Patch were easily managed by simple 
removal of Neuro-Patch in an outpatient clinical setting, 
which was both time and cost-effective. Primary closure 
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Fig. 3. Case 7. Infected Neuro-Patch–wrapped implant. (A) Neu-
ro-Patch exposure with severe discharge due to implant infection, 
(B) removed hydroxyapatite implant and Neuro-Patch, (C) well 
healed conjunctival socket postoperatively. Written informed 
consent from the patient was obtained.
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was not necessary for small areas of exposure. Thus, most 
cases of HA exposure in a wrapped implant can be suc-
cessfully treated by simple removal if detected and man-
aged early. However, removal should be considered if the 
implant is severely infected.
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